How better to keep self deal alive to revimmune when advent and cognate weren't enough. Have your paid pumps generate some hype around this early stage data and company. We can pivot to combination therapy and kick the goal posts 200 more yards down the road. Let's keep continuing this conflict of interest scam to more unsuspecting retail. Keep adding fleas to this POS. The story keeps getting better and better.....unbelievable. And you all wonder why you are on the POS OTC.
All this is noise....the only thing that can save this is both approval and buyout. Approval alone is not even enough with no path to profitability.
I think there is a tendency to project how they will deal with revimmune’s patent interest in the dc + ci patent.
IMO, LP would have had that worked out in some agreement of understanding with the three or four main parties back when she had the patent app filed in 2015.
I simply can’t worry about these things. I assume it’s just a very good thing Europe, in addition to a few countries outside Europe, already granted the combination patent.
The Global Device & Packaging Unit is a global business Unit in Sanofi M&S which develops and maintains Sanofi`s parenteral injection systems like Insulin Pens, Autoinjectors, Large Volume Devices, infusion systems and Pre-Filled Syringes. The Unit is a project-centric organization which is executing development and LCM projects of drug delivery devices for mAbs, vaccines, peptides, genomics etc. and supports device product maintenance post launch.
Utilizing large datasets including genetic, transcriptomic, single cell, proteomic, imaging and electronic medical record data to train foundational deep learning models on disease specific context.
The Non-Clinical Efficacy and Safety (NCES) team, within the Global Biostatistics and Programming Department of Sanofi R&D, contributes to reliability, scientific quality and optimization of Projects/Programs support from "target identification" to "compounds in development” by providing appropriate non clinical statistical support for efficacy and safety internal or external studies for all R&D entities.